NeuroPace Statistics
Total Valuation
NeuroPace has a market cap or net worth of $396.82 million. The enterprise value is $402.64 million.
| Market Cap | 396.82M |
| Enterprise Value | 402.64M |
Important Dates
The next confirmed earnings date is Wednesday, May 8, 2024, after market close.
| Earnings Date | May 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
NeuroPace has 28.34 million shares outstanding. The number of shares has increased by 5.11% in one year.
| Shares Outstanding | 28.34M |
| Shares Change (YoY) | +5.11% |
| Shares Change (QoQ) | +3.05% |
| Owned by Insiders (%) | 3.95% |
| Owned by Institutions (%) | 79.19% |
| Float | 11.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.07 |
| Forward PS | 5.19 |
| PB Ratio | 19.21 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.71, with a Debt / Equity ratio of 3.51.
| Current Ratio | 5.71 |
| Quick Ratio | 4.86 |
| Debt / Equity | 3.51 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.87 |
Financial Efficiency
Return on equity (ROE) is -153.80% and return on invested capital (ROIC) is -29.20%.
| Return on Equity (ROE) | -153.80% |
| Return on Assets (ROA) | -31.70% |
| Return on Capital (ROIC) | -29.20% |
| Revenue Per Employee | $382,579 |
| Profits Per Employee | -$192,725 |
| Employee Count | 171 |
| Asset Turnover | 0.63 |
| Inventory Turnover | 1.65 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +203.03% in the last 52 weeks. The beta is 2.09, so NeuroPace's price volatility has been higher than the market average.
| Beta (1Y) | 2.09 |
| 52-Week Price Change | +203.03% |
| 50-Day Moving Average | 14.61 |
| 200-Day Moving Average | 9.66 |
| Relative Strength Index (RSI) | 50.35 |
| Average Volume (30 Days) | 105,985 |
Short Selling Information
The latest short interest is 85,915, so 0.30% of the outstanding shares have been sold short.
| Short Interest | 85,915 |
| Short Previous Month | 30,926 |
| Short % of Shares Out | 0.30% |
| Short % of Float | 0.77% |
| Short Ratio (days to cover) | 0.86 |
Income Statement
In the last 12 months, NeuroPace had revenue of $65.42 million and -$32.96 million in losses. Loss per share was -$1.27.
| Revenue | 65.42M |
| Gross Profit | 48.12M |
| Operating Income | -27.17M |
| Pretax Income | -32.96M |
| Net Income | -32.96M |
| EBITDA | -22.83M |
| EBIT | -24.44M |
| Loss Per Share | -$1.27 |
Balance Sheet
The company has $66.58 million in cash and $72.40 million in debt, giving a net cash position of -$5.82 million or -$0.21 per share.
| Cash & Cash Equivalents | 66.58M |
| Total Debt | 72.40M |
| Net Cash | -5.82M |
| Net Cash Per Share | -$0.21 |
| Equity / Book Value | 20.65M |
| Book Value Per Share | 0.73 |
| Working Capital | 76.49M |
Cash Flow
In the last 12 months, operating cash flow was -$19.70 million and capital expenditures -$173,000, giving a free cash flow of -$19.87 million.
| Operating Cash Flow | -19.70M |
| Capital Expenditures | -173,000 |
| Free Cash Flow | -19.87M |
| FCF Per Share | -$0.77 |
Margins
Gross margin is 73.56%, with operating and profit margins of -41.54% and -50.38%.
| Gross Margin | 73.56% |
| Operating Margin | -41.54% |
| Pretax Margin | -50.38% |
| Profit Margin | -50.38% |
| EBITDA Margin | -34.90% |
| EBIT Margin | -37.36% |
| FCF Margin | -30.38% |
Dividends & Yields
NeuroPace does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.11% |
| Shareholder Yield | -5.11% |
| Earnings Yield | -8.30% |
| FCF Yield | -5.01% |
Analyst Forecast
The average price target for NeuroPace is $17.00, which is 21.43% higher than the current price. The consensus rating is "Buy".
| Price Target | $17.00 |
| Price Target Difference | 21.43% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NeuroPace has an Altman Z-Score of -3.1 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.1 |
| Piotroski F-Score | 3 |